

Special Issue

Engineered TCR and CAR Cells for Immunotherapy of Solid Tumors

Message from the Guest Editors

The Special Issue of *Biomolecules* is titled “Engineered TCR and CAR Cells for Immunotherapy of Solid Tumors”. Use of adoptive cell therapy strategies to treat cancer, including solid tumors, continues to be a rapidly evolving therapeutic paradigm. The successful clinical application of engineered T cell receptor (TCR) or chimeric antigen receptor (CAR) T cells to treat B cell malignancies, such as leukemia, lymphoma and multiple myeloma, has quickly transformed modern medicine. These concepts have been expanded to include additional immune cell sources, such as natural killer (NK) cells, dendritic cells (DC) and macrophages. This Special Issue will highlight current and emerging concepts and strategies to target and eliminate solid tumors using engineered immune cells, including recent progress in preclinical and clinical studies that may direct development of more efficacious therapeutic strategies. The journal *Biomolecules* encourages clinicians and researchers to submit their original research or reviews on use of modified immune cells to treat solid tumors for consideration of publication in this Special Issue.

Guest Editors

Dr. Michael Morgan

Institute of Experimental Hematology, Hannover Medical School,
30625 Hannover, Germany

Dr. Vinagolu K. Rajasekhar

Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Deadline for manuscript submissions

closed (31 December 2023)



Biomolecules

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.4
Indexed in PubMed



mdpi.com/si/128418

Biomolecules
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomolecules@mdpi.com

[mdpi.com/journal/
biomolecules](https://mdpi.com/journal/biomolecules)





Biomolecules

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.4
Indexed in PubMed



[mdpi.com/journal/
biomolecules](https://mdpi.com/journal/biomolecules)



About the Journal

Message from the Editorial Board

Biomolecules is a multidisciplinary open-access journal that reports on all aspects of research related to biogenic substances, from small molecules to complex polymers. We invite manuscripts of high scientific quality that pertain to the diverse aspects relevant to organic molecules, irrespective of the biological question or methodology. We aim for a competent, fair peer review and rapid publication. Please look at some of the exciting work that has been published in *Biomolecules* so far. We would be delighted to welcome you as one of our authors.

Editors-in-Chief

Prof. Dr. Peter E. Nielsen

Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3C, DK-2200 Copenhagen, Denmark

Prof. Dr. Lukasz Kurgan

Department of Computer Science, Virginia Commonwealth University, Richmond, VA 23284, USA

Author Benefits

Open Access

– free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Biochemistry)